Company

Therapeutic Leadership

Volker Germaschewski, PhD

Co-Head of Haematology

Dr Volker Germaschewski, Co-Head of Haematology, joined Kymab in 2011. He brings 18 years’ experience in biopharmaceutical discovery and development in biotech and pharma and worked with all major technology platforms for the discovery of therapeutic monoclonal antibodies.

His previous experience includes roles as Section Head Domain Antibody Discovery and Team Leader Antibody Engineering at GSK where he was instrumental in re-establishing a therapeutic antibody portfolio after the creation of GSK in 2000.

Paul Kellam, PhD

Vice-President, Infectious Disease & Vaccines

Professor Paul Kellam, Vice-President of Vaccines & Infectious Disease, has a distinguished career in virology and published over 190 articles, having previously worked at the Wellcome Trust Sanger Institute, where his team uncovered a crucial human genetic variant that affects the outcome of influenza infection.

Professor Kellam is an internationally recognised expert in the genetics of emerging infectious disease, such as Ebola and the MERS coronavirus, as well as the biology of virus and host interactions. In addition to his role with Kymab, Professor Kellam serves as part-time Professor of Virus Genomics at Imperial College London.

Matthew McCourt

Vice-President, Immuno-oncology

Matthew McCourt, Vice-President of Immuno-oncology, has been promoted internally, having joined Kymab in 2015. He brings 25 years’ experience in biopharmaceutical research and development.

His previous experience includes roles as Director of Oncology Biology at MedImmune, where his team drove the discovery and preclinical development of MedImmune’s immuno-oncology portfolio of biologics, and Head of Pharmacology at Cambridge Antibody Technology.

Igor Theurl, MD, PhD

Co-Head of Haematology

Professor Igor Theurl, Head of Haematology, is a board-certified practicing physician and experimental scientist whose work includes the area of anaemia of chronic disease and has published more than 70 articles.

Alongside his leadership role with Kymab, Professor Theurl will serve part-time as Professor of Medicine at the Medical University of Innsbruck, Austria.

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline